| Code | CSB-RA620892MB1HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is a research-grade biosimilar to Idactamab, designed to target SLC1A5 (solute carrier family 1 member 5), also known as ASCT2 (alanine, serine, cysteine transporter 2). SLC1A5 functions as a sodium-dependent neutral amino acid transporter that mediates the cellular uptake of glutamine and other essential amino acids. This transporter plays a critical role in cellular metabolism, protein synthesis, and mTOR signaling pathway activation. SLC1A5 is frequently overexpressed in various malignancies, including triple-negative breast cancer, colorectal cancer, and hepatocellular carcinoma, where it supports the heightened metabolic demands of rapidly proliferating tumor cells and contributes to cancer progression and therapeutic resistance.
Idactamab represents a therapeutic antibody developed to target SLC1A5-expressing cancer cells, functioning through antibody-dependent cellular cytotoxicity mechanisms. This biosimilar provides researchers with a valuable tool for investigating SLC1A5 biology, exploring glutamine metabolism in cancer, evaluating therapeutic targeting strategies, and studying the role of amino acid transport in tumor microenvironments and metabolic reprogramming.
There are currently no reviews for this product.